Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | KANAK ENTERPRISES | 1 | ₹2,628 |
| 2 | Schedule 2 | KANAK ENTERPRISES | 1 | ₹900 |
| 3 | Schedule 3 | KANAK ENTERPRISES | 1 | ₹1,314 |
| 4 | Schedule 4 | M/S SRD HEALTH CARE | 1 | ₹76,072.50 |
| 5 | Schedule 5 | Not yet disclosed by govt. | 17 | - |
Tender Value
₹93,598.50
EMD Value
Exempted
Closing Date
17 Oct 2024, 11:00 amClosed
DGLP MEDICINE 101
6951430
GEM/2024/B/5441363
Two Packet Bid
Clobazam 5 mg Tab,Acenocoumarol 1 mg Tab,Diltiazem 60 mg Tab,Human Insulin Analogue Glargine Inj, 1
30 days
Rajasthan; Ajmer
Item wise evaluation
BOQ
3 documents required · 3 mandatory
10%
Exempted
17 Oct 2024
26 Sept 2024
17 Oct 2024
| Item No | Item Title | Description | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|---|
| 1 | Clobazam 5 mg Tab | As per pdf | 3,600 | No | AJMER | 30 |
| 2 | Acenocoumarol 1 mg Tab | As per pdf | 1,200 | No | AJMER | 30 |
| 3 | Diltiazem 60 mg Tab | As per pdf | 1,800 | No | AJMER | 30 |
| 4 | Human Insulin Analogue Glargine Inj, 100 IU Oblique ml Recombinant DNA origin 300 IU Disposable Pen with 5 needles per pen | As per pdf | 315 | Pen | AJMER | 30 |
| 5 | Ondansetron Syp 2 mg oblique 5ml in Bott of 30 ml | As per pdf | 600 | Bott | AJMER | 30 |
| 6 | Ondansetron 8mg Tab | As per pdf | 9,000 | No | AJMER | 30 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_6951430.pdf
GEM_BID
dglp_medicne_101_2024-09-26-09-05-45_d4a4db4948cecb7e1ba1a092bcec13ad.pdf
BOQ
boq_item_sample_file_-15_2024-09-26-09-05-45_1a9c409aa66387d353af3eac1115d896.csv
BOQ
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .